LAAB Medicine AstraZeneca supplies in this round will be allocated and used for pre-exposure prophylaxis against COVID-19. In adults and young people (aged 12 and over and weighing at least 40 kg) with immunocompromised conditions. and who have an insufficient immune response to the COVID-19 vaccine, or patients who are unable to receive the COVID-19 vaccine. To be an alternative to Thailand in the ongoing fight against COVID-19
The supply comes after more than 7,000 LAAB units were allocated in July to the first group of end-stage renal failure patients with a further 209,000 units to Thailand by the end of this year. According to the purchase contract signed by AstraZeneca and the Department of Disease Control at the beginning of July
Mr. James Teek, Chairman of AstraZeneca (Thailand) Co., Ltd. Co., Ltd. said: “A long-acting conjugated antibody drug, or LAAB, is a ready-made immunosuppressant that could be an alternative way to help prevent COVID-19. to vulnerable populations in Thailand, such as immunocompromised people with inadequate immune responses to vaccines AstraZeneca cooperates and supports the Ministry of Public Health to implement the Immunization Plan to cover people throughout the country. We therefore offer alternatives to those at high risk of serious illness from COVID-19. which is caused by the Omicron species It reinforces AstraZeneca’s commitment to keeping everyone safe from this pandemic.”
AstraZeneca’s LAAB drug Received conditional registration of drug formulations in Thailand In June 2008 by the Food and Drug Administration (FDA) for use for pre-exposure prophylaxis of the coviral-19 virus. In adults and young people aged 12 years and over and weighing at least 40 kg, those who have been vaccinated and those who have never been vaccinated before, the Department for Disease Control has set guidelines for use this drug with “group 607”, a vulnerable group at risk of COVID-19 or unable to be vaccinated
LAAB is currently used for pre-exposure prophylaxis of the COVID-19 virus in more than 30 countries worldwide, including the United States, Canada, France, Germany, Spain, Australia, New Zealand, China, Egypt, Malaysia, South Korea and Vietnam. Senneca has just been registered as a drug for pre-exposure prophylaxis against the COVID-19 virus. and treatment for COVID-19 Symptoms in Japan More and more applications for the approval of drugs for preventive and therapeutic purposes are being submitted in many countries around the world.
AZD7442 AstraZeneca or LAAB
AZD7442 (LAAB AstraZeneca) is derived from B cells donated by a person previously ill with SARS-CoV-2, discovered by Vanderbilt University Medical Center. AstraZeneca was authorized for further development in June 2020. The two human monoclonal antibodies will have different specifications. to bind to the spike protein covid-19, or SARS-CoV-2, at two different points, and was further developed by AstraZeneca. To extend the half-life (half-life) to increase the longevity of antibodies. and modified for Fc Receptor binding and reduced Complement type C1q 3. By extending the half-life, the longevity of the antibody was more than threefold. Compared to conventional antibodies 4-6, Phase 3 trial data showed that the level of antibodies that can inhibit viral proliferation. Neutralizing antibodies persist for a period of no less than 6 months, and modifications to reduced Fc receptor binding may reduce the risk of hyperthyroidism. antibody-dependent enhancement (ADE), a phenomenon in which viral antibodies stimulate rather than prevent infection 7
About AstraZeneca
AstraZeneca (the stock ticker AZN on the LSE/STO/ Nasdaq) is a leading global biopharmaceutical company. Focus on the invention, development and distribution of medicines for the treatment of diseases. especially in cancer drugs Cardiovascular, Kidney, and Metabolic drugs and respiratory medicines AstraZeneca located in Cambridge united kingdom It operates in more than 100 countries and has millions of patients worldwide benefiting from innovative medicines. from AstraZeneca For more information, visit the website. astrazeneca.co and Twitter channel @AstraZeneca
1. Food and Drug Administration of Thailand, Ministry of Health http://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug_ex.aspx?Newcode=U1DR2C1072650000511C. (Last accessed September 2022).
2. Dong J, et al. Genetic and Structural Basis for Neutralization of a SARS-CoV-2 Variant by a Cocktail of Two Antibodies. Nat Microbiol. 2021; 6(10): 1233-1244. doi:10.1038/s41564-021-00972-2.
3. Loo YM, et al. AZD7442 Shows Prophylactic and Therapeutic Efficacy in Non-Human Primates and Extended Half-Life in Humans. Sci Transl Med. 2022; 14(635): eabl8124.
4. Robbie GJ, et al. A New Fc-Modified Investigational Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults. Antimicrobial Agents and Chemotherapy. 2013; 57(12):6147. doi:10.1128/AAC.01285-13.
5. Griffin MP, et al. Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Prefusion Respiratory Syncytial Virus F-Targeting Monoclonal Antibody with Extended Half-Life, in Healthy Adults. Antimicrobial Agents Chemother. 2017;61(3).
6. Domachowske JB, et al. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-Life of a Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Pediatr Infect Dis J. 2018; 37(9):886-892.
7. van Erp EA, et al. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease. Frontal immune. 2019;10 (MAR).
